Objective
to compare whether transcatheter mitral-valve repair (TMVR) with MitraClip improves clinical outcomes in patients with heart failure and severe functional mitral regurgitation
Study
randomised, multicentre, semi-label
Population
i. severe secondary mitral regurgitation. ii. Left ventricular ejection fraction between 15 and 40%. iii. Symptomatic heart failure
Endpoints
the primary efficacy outcome was a composite of death from any cause or unplanned hospitalisation for heart failure at 12 months


Conclusion
the rate of death or unplanned hospitalisation for heart failure at 1 year did not differ between patients allocated to TMVR versus medical therapy alone
Obadia et al. N Eng J Med. 2018;379:2297-306